Extrait

This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in patients with Hepatitis C chronic infection identified as non responders to the standard bi-therapy alone.

Critère d'inclusion

• Hepatitis C

Liens

• ictrp
• nct